Contents
On this page
- Product protection and usability: two distinct evidence bases
- The four evaluation areas for container closure systems
- Packaging within the pharmaceutical development rationale
- Evidence on compliance aids and adherence packaging
- Regulatory classification of packaging as a device
- Writing the container closure justification
- Limitations of the available sources
- Key points
- Application to your study
- Frequently asked questions
Academy · Research Writing · Drug packaging design
The Role of Packaging Design in Drug Development: Regulatory Requirements and Evidence
Packaging has two functions, protecting the product and enabling its use by the patient, and only the first is supported by a settled regulatory framework. Container closure expectations are specified and reviewable. The claim that packaging design improves adherence rests on a considerably thinner evidence base than industry discussion implies, and this article treats the two separately.
This article is deliberately narrow in scope. Container closure requirements are well defined, and a programme can be planned against them with confidence. The second part of the subject (blister wallets, calendar packs, multi-compartment compliance aids and labelling for older users) is often discussed as though the evidence were comparable, which it is not. This article reports only what verifiable sources support and identifies the gaps as such. No reliable figure for the extent to which adherence packaging improves outcomes could be identified.
Learning objectives
- The four areas against which a container closure system must be evaluated, and the evidence required for each
- The reasons FDA container closure expectations are currently in transition, and planning in the context of a draft guidance
- The position of the container closure within an ICH Q8(R2) development rationale rather than alongside it
- The findings of one user study regarding why people were given a compliance aid, and the significance of that finding
- The point at which packaging becomes a device, and the consequences for the regulatory route
- Writing a container closure justification that a reviewer can assess
Common misconceptions
- “Packaging is selected after the formulation is fixed.” ICH Q8(R2) places the container closure system within the quality target product profile, which is written at the outset. For high-concentration biologics, the container and the formulation cannot be selected independently.
- “Child-resistant packaging is an FDA requirement.” In the United States, child-resistant packaging is regulated by the Consumer Product Safety Commission under the Poison Prevention Packaging Act, not by FDA as part of drug approval. These are separate obligations with separate test standards, and development teams frequently assume that one covers the other.
- “Adherence packaging is proven to improve outcomes.” No evidence supporting this as a general claim could be identified. The available evidence is narrower and more informative: in the user study by Chin and colleagues, 12 of 61 compliance-aid users (20%) did not know why the aid had been provided.
- “A compliance aid is always an improvement on the original pack.” In the same study, 5 users (8%) had considered returning to the original packaging. Repackaging also removes the product from the container closure system in which its stability data were generated.
Product protection and usability: two distinct evidence bases
Packaging serves two functions. The first is to protect the product without altering it: to exclude moisture, oxygen and light, to avoid leaching any substance into the product, to avoid sorption of the active ingredient or the preservative, and, for sterile products, to maintain integrity throughout the shelf life. This function has a mature regulatory framework, specified test approaches and a reviewable evidence package.
The second function is usability: the pack must be openable, legible and memorable for the person taking the medicine, who may be eighty-five years old, with arthritic hands and four other prescriptions. This function has a substantial design literature but a limited clinical evidence base, and most of the overclaiming in the field arises in the gap between the two.
The distinction is of practical importance, because the first function is a chemistry, manufacturing and controls (CMC) matter on which the regulatory submission depends, whereas the second is a human factors matter that principally affects whether the product performs as intended after approval. Both are important, but they are not interchangeable, and strong usability evidence will not compensate for a weak extractables package.
The four evaluation areas for container closure systems
FDA’s container closure framework organises the evaluation into four areas, and they have remained stable for a long time even as the guidance behind them is revised 1. Protection asks whether the system shields the product from the environmental factors that degrade it — light, moisture, oxygen, microbial ingress — over the proposed shelf life and storage conditions 1. Compatibility asks whether the system and the product change each other: leachables migrating into the product, sorption of active ingredient or preservative onto the contact surface, and any change in the container itself. Safety asks whether the materials of construction, and anything they release, are acceptable at the resulting exposure. Performance asks whether the system functions as intended, which for a delivery system means dose accuracy and reproducibility rather than only containment.
The governing document is currently in transition, and that has practical consequences. FDA’s draft guidance Container Closure Systems for Human Drugs and Biological Products is intended to replace the 1999 guidance and its 2002 questions-and-answers companion 1. Because it is a draft, it represents the Agency’s current thinking and is open for comment rather than binding, so the 1999 document remains the formally issued guidance while the draft indicates where review expectations are heading. The workable position is to design the programme against the draft, since that is where reviewers are likely to look, and to confirm the filing position with the sponsor’s regulatory affairs function before submission.
Outside the United States, the requirements are structured differently rather than being less stringent. The European Pharmacopoeia general chapters on containers and on materials used for containers carry much of the technical expectation, and the pharmaceutical quality requirements sit in the marketing authorisation application rather than in a single container closure guidance. It should not be assumed that a US container closure package will transfer unchanged; the expectations of each target authority should be confirmed, jurisdiction by jurisdiction.
The four areas a container closure system is evaluated against
| Area | The question | Typical evidence | Where it is commonly thin |
|---|---|---|---|
| Protection | Does the system shield the product from the factors that degrade it, for the proposed shelf life and storage conditions? | Moisture vapour and oxygen transmission data for the system; photostability; stability data generated in the proposed pack | Stability run in a surrogate container and extrapolated to the marketed one |
| Compatibility | Do the product and the system change each other? | Extractables study on materials of construction; leachables study on the product in the pack over time; sorption assessment for active ingredient and preservative | Extractables done, leachables deferred; sorption of preservative not assessed in multidose products |
| Safety | Are the materials, and anything they release, acceptable at the resulting exposure? | Material composition and compliance data; toxicological assessment of identified leachables at measured levels | A toxicological assessment that stops at “below the threshold” without stating which threshold and why it applies |
| Performance | Does the system function as intended, including as a delivery system? | Functional testing (dose accuracy, delivered volume, actuation force); container closure integrity for sterile products; use-related risk analysis where a user operates it | Treated as a packaging engineering matter rather than part of the product’s performance claim |
The four-area structure is the one used in FDA’s container closure guidance for human drugs and biological products, whose 1999 version and 2002 questions-and-answers companion the current draft guidance is intended to replace. The “commonly thin” column is our review experience, not a published finding.
Packaging within the pharmaceutical development rationale
ICH Q8(R2) defines quality by design as a systematic approach to development that begins with predefined objectives and emphasises product and process understanding and process control, based on sound science and quality risk management 5. The container closure system is named in the quality target product profile, which is written at the start of that process — not appended to it 5,12. This placement is significant: the packaging is one of the predefined objectives against which the formulation and process are developed.
This has a concrete consequence for sequencing. If the target product profile commits to a particular presentation — a prefilled syringe, a multidose vial, a blister for a given regimen — then the formulation work must be compatible with that presentation from the beginning, and the stability programme must be run in it. Conversely, if the presentation is left open, the stability programme will eventually have to be run twice. Jiskoot and colleagues, in the Journal of Pharmaceutical Sciences, make this point most forcefully for high-concentration monoclonal antibody formulations intended for subcutaneous administration, where viscosity and injection force couple the formulation, the container and the delivery device so tightly that selecting them in sequence is not feasible 15.
The material side of this decision is the same kind of problem as excipient selection, and it is discussed at length in selecting materials for drug development. Our guide to the ICH guidelines covers how Q8(R2) relates to the quality risk management and quality system guidelines around it.
Evidence on compliance aids and adherence packaging
At this point the evidence becomes limited, so this section is brief and specific. Chin and colleagues surveyed users and carers about pharmacy-filled multi-compartment medication compliance aids — the weekly trays dispensed to people managing several medicines 25. Of 61 users, 12 (20%) did not know why the aid had been provided to them, and 5 (8%) had considered returning to their original packaging 25. These two figures merit more attention than their size suggests. An intervention that one fifth of its recipients cannot explain is functioning not as a designed intervention but as a default. Moreover, a measurable minority preferred their previous arrangement.
The design literature points in a compatible direction. Carli Lorenzini and Olsson, in the ICED proceedings, examine the gap between pharmaceutical packaging design and the capabilities and preferences of elderly users, and treat it as a design-process failure rather than a materials one: the intended users of the pack are not involved when it is specified 22. That framing is useful because it suggests that the remedy is procedural — involving the intended users early in the presentation decision — rather than a particular pack format.
Repackaging carries a quality consequence that is easily overlooked in this context. When a product is moved out of its licensed container closure system into a compliance aid, the stability data supporting its shelf life were not generated in the container it is now in. That is a known and generally accepted practice in dispensing, but it is a change in the conditions under which the product was tested, and for moisture-sensitive or light-sensitive products it is a real rather than a theoretical consideration.
Source: Chin K, Hegarty A, Thielemans L, Schiff R. Thinking outside the box: exploring user and carer perceptions of pharmacy-filled multi-compartment medication compliance aids. Reported as a society meeting abstract; 61 users surveyed, so these proportions carry wide uncertainty and are presented as an observation rather than an estimate.
Regulatory classification of packaging as a device
A container that delivers a dose is doing more than containing. Prefilled syringes, autoinjectors, pen injectors, metered inhalers, nasal sprays and on-body injectors all carry a functional performance requirement — dose accuracy, reproducibility, actuation force, use-related risk — and they change the regulatory structure of the product.
The routes differ by jurisdiction and should be established early. In the United States, a product combining a drug and a device constituent is regulated as a combination product, with the primary mode of action determining which centre takes the lead on review. In the European Union, EU MDR 2017/745 introduced through its Article 117 a requirement that the application for an integral drug-device combination include a notified body opinion on the device part, which means a notified body interaction inside what teams often plan as a purely medicinal submission. Those are structurally different arrangements with different timelines; both should be settled with the regulatory affairs function at the point the presentation is chosen, not at the point the dossier is compiled.
Where a device constituent is involved, the biological evaluation question also appears, since the fluid path and any patient-contacting part fall under the device framework 3. That is a separate discipline with its own standards, and it is discussed in selecting materials for a medical device.
Writing the container closure justification
Most container closure sections reviewed by Pubrica name the pack and assert that it is standard. This is not a justification, because “standard” is a statement about the market rather than about the product. The four-area framework provides the structure a reviewer expects, and applying it explicitly requires only a paragraph.
A container closure justification, asserted versus argued
Asserts that the pack is standard
The drug product will be supplied in white high-density polyethylene bottles with child-resistant polypropylene closures and induction seals. This container closure system is widely used for oral solid dosage forms and is considered suitable for the product. Stability studies are ongoing.
Protection against what? No degradation pathway is named, so the choice of barrier cannot be judged.
Was stability run in this pack? “Ongoing” does not say in which configuration.
Extractables and leachables? Not mentioned, which a reviewer will interpret as not performed.
Which threshold, and why? No safety argument at all.
Is the child-resistant claim part of this submission? Ambiguous, and the obligation falls under a different regulator.
Answers the four questions
The product is supplied in a 100 mL white high-density polyethylene bottle with a polypropylene closure and induction-sealed liner, with a desiccant insert. Protection: the active ingredient is moisture-sensitive, degrading via hydrolysis, so the system was selected for moisture barrier; registration stability is run in the marketed configuration, including the desiccant, at the proposed storage condition, and photostability was assessed in the opaque bottle as marketed. Compatibility: an extractables study on the bottle, closure and liner materials was followed by a leachables study on the product in the marketed pack at the registration timepoints, with sorption of the active ingredient onto the liner assessed directly; no leachable exceeded the analytical evaluation threshold applied. Safety: the toxicological assessment of identified leachables is given in Section 3.2.P.7, with the threshold used and its basis stated. Performance: the system is not a delivery system; the functional requirement is the child-resistant performance of the closure, which is addressed separately under the Poison Prevention Packaging Act and is not part of this application.
The degradation pathway is named, so the barrier requirement follows from the chemistry.
Stability is stated to be in the marketed configuration, desiccant included.
Extractables, leachables and sorption are each addressed, in that order, on the marketed pack.
The toxicological threshold is cross-referenced with its basis rather than asserted.
The regulatory boundary is drawn explicitly: child resistance is a separate obligation under a separate instrument.
The second version is the same pack and, mostly, the same studies. What it adds is the reasoning that makes each study the right study, and one sentence drawing a boundary — that child-resistant performance is regulated separately in the United States — which removes an ambiguity reviewers otherwise have to resolve by asking.
Limitations of the available sources
Several matters that are usually discussed with confidence could not be found in the verified source pool for this page. No figure is given here for the magnitude of adherence improvement attributable to packaging design, because no sufficiently reliable source could be identified. Nor is any information given on the cost-effectiveness of adherence packaging or on the contribution of packaging-related error to medication incidents. These claims are not doubted in principle; they cannot be made with attribution, and a page that invented them would be less useful than one that acknowledges their absence.
The one user study cited here is itself a limited source: a survey abstract reported to a society meeting, with 61 users. That is sufficient to support the specific observation that one fifth of recipients did not know why they had been given the aid; it is not sufficient to support a general claim about compliance aids and outcomes, and it has not been used in that way 25.
The subject of the adjacent literature should also be noted. The substantial recent evidence base on medication burden in older people — the deprescribing trials reviewed by Omuya and colleagues in the International Journal of Pharmacy Practice, the pooled analyses in JAMDA and the long-term care review by Carollo and colleagues — concerns reducing the number of medicines prescribed, not how they are packaged 6,9,11. It is sometimes cited in support of packaging interventions. It does not support them, and conflating the two overstates what is known. Where a defensible answer on adherence packaging is required for a business case or a submission, it should be treated as a systematic review question with a protocol, and the review should be expected to conclude that the evidence is limited.
Key points
Key points
Container closure should be treated as part of the formulation decision and planned against the four areas of protection, compatibility, safety and performance. FDA expectations are in transition, with a draft guidance intended to replace the 1999 guidance and its 2002 questions-and-answers companion; design should follow the draft, and the filing position should be confirmed with regulatory affairs, because a draft represents current thinking rather than a requirement. Where the container delivers a dose, the product becomes a combination product in the United States and, in the European Union, falls under the Article 117 notified body opinion requirement; these are different structures with different timelines. Claims regarding usability should be more modest than is customary in the field: the strongest attributable finding is that 12 of 61 compliance-aid users did not know why the aid had been provided.
Application to your study
Application to your study
- Identify the degradation pathway before specifying a barrier. Hydrolysis, oxidation and photodegradation each determine which barrier property matters and what the protection argument must demonstrate.
- Include the container closure system in the quality target product profile from the outset. If the presentation is left undetermined, the stability programme may need to be conducted twice.
- Conduct registration stability studies in the marketed configuration, including desiccant, liner and fill volume. Data from surrogate containers will require bridging.
- Conduct extractables studies, then leachables studies, then the toxicological assessment, and state the threshold applied and the reason it applies. An assessment that concludes only “below threshold” invites further questions.
- Assess sorption explicitly for preservatives and low-dose actives. Loss onto the contact surface affects both potency and preservative efficacy, and its assessment is frequently omitted.
- Determine whether the presentation constitutes a combination product, and in which markets. In the United States, the primary mode of action determines the lead centre; the EU route introduces a notified body opinion into a medicinal product application. Both involve lead times.
- Distinguish the child-resistance obligation from the drug application. In the United States it falls under the Consumer Product Safety Commission and the Poison Prevention Packaging Act; the position in each other market should be confirmed.
- Where an adherence or usability claim is intended, determine at the outset what evidence would support it. Involve intended users in the presentation decision, and avoid reliance on the deprescribing literature, which concerns reducing medicines rather than packaging them.
Frequently asked questions
Four areas, in the structure FDA’s container closure guidance has long used. Protection: whether the system shields the product from the environmental factors that degrade it, for the proposed shelf life and storage conditions. Compatibility: whether the product and the system change each other, covering leachables migrating in, sorption of active ingredient or preservative out, and any change to the container. Safety: whether the materials of construction and anything they release are acceptable at the resulting exposure. Performance: whether the system works as intended, which for a delivery system means dose accuracy and reproducibility, and for sterile products includes container closure integrity. Each area needs its own evidence; a strong result in one does not cover another.
This matter is unsettled and requires careful handling. FDA has issued a draft guidance, Container Closure Systems for Human Drugs and Biological Products, intended to replace the 1999 guidance and its 2002 questions-and-answers companion. A draft guidance represents the Agency’s current thinking and is open to comment; it is not binding, and the 1999 document remains the formally issued version. In practice, reviewers are likely to be reading with the draft’s expectations in mind, so the defensible approach is to design the extractables, leachables and integrity programme against the draft while confirming the filing position with the sponsor’s regulatory affairs function. Pubrica describes what the documents ask for; it does not determine the sponsor’s filing position.
No attributable figure is available to answer this question, and it is preferable to state this than to produce one. The evidence that can be sourced is narrow: Chin and colleagues, surveying users and carers of pharmacy-filled multi-compartment compliance aids, found that 12 of 61 users (20%) did not know why the aid had been provided and that 5 (8%) had considered returning to their original packaging. That is an observation about how such aids are experienced, from a small survey reported as a meeting abstract — not an effect estimate. The design literature, including Carli Lorenzini and Olsson, treats the mismatch between packaging and older users as a design-process problem. An adherence claim should be treated as a question requiring its own review.
Not in the United States. Child-resistant packaging is regulated by the Consumer Product Safety Commission under the Poison Prevention Packaging Act, with its own test standards and its own compliance route, separate from FDA’s review of the container closure system in a drug application. The two obligations are frequently conflated, with the result that a team believes a single package qualification covers both. They should be planned and documented separately, and the drug application should state explicitly where the child-resistance claim is handled. In other jurisdictions the arrangement differs, so it should be confirmed market by market with the regulatory affairs function.
When it delivers the dose rather than only containing it — prefilled syringes, autoinjectors, pen injectors, metered inhalers, nasal sprays, on-body injectors. In the United States the product is then a combination product, and the primary mode of action determines which FDA centre leads the review. In the European Union, EU MDR 2017/745 introduced through Article 117 a requirement that an application for an integral drug-device combination include a notified body opinion on the device part, which inserts a notified body interaction into a medicinal product submission. These are different structures with different lead times, and the patient-contacting parts also bring the device biological evaluation framework into scope.
Early development data can be generated in that way, but registration stability should be run in the marketed configuration — the same resin and grade, the same closure and liner, the same fill volume, and the same secondary components such as a desiccant if one is used. The protection and compatibility arguments are properties of the system, not of the material in isolation, so data from a surrogate container leave a bridging question that a reviewer is entitled to raise. Changing the pack after registration stability has started is one of the more common reasons a programme runs stability twice, and it is usually avoidable by fixing the presentation in the target product profile.
It is a change in the conditions under which the product was tested, and should be identified as such. The shelf life assigned to a product is supported by stability data generated in its licensed container closure system; once tablets are moved into a weekly multi-compartment tray they are no longer in that system, and for moisture-sensitive or light-sensitive products that is significant. Dispensing practice accepts this, and the balance of benefit is a clinical judgement rather than a manufacturing one. For a manufacturer the practical implication is different: if the product is expected to be repackaged in routine use, that is an argument for characterising its behaviour outside its pack, and for stating this in the product information.
It should be treated as a review question with a protocol rather than an unstructured literature search, because the available material is heterogeneous and much of it is promotional. The population, the packaging intervention, the comparator and the outcome should be specified before searching; whether self-reported adherence, refill-based measures or clinical outcomes will be accepted should be decided in advance, since they behave very differently; and the design and human factors literature should be searched as well as the clinical databases. The conclusion should be expected to be that the evidence is limited and heterogeneous. That is a usable finding for a business case, since it indicates that the claim must be generated rather than cited.
References
- U.S. Food and Drug Administration. Container Closure Systems for Human Drugs and Biological Products (draft guidance). U.S. Food and Drug Administration. 2026. read 9 October 2026. packagingdigest.com
- U.S. Food and Drug Administration, CDER Office of Generic Drugs. FDA's Inactive Ingredient Database (IID) Program & AI Consideration. FDA FY2026 Generic Drug Science and Research Initiatives Public Workshop. 2026. read 9 October 2026. fda.gov
- U.S. Food and Drug Administration (CDRH, CBER). Use of International Standard ISO 10993-1, "Biological evaluation of medical devices - Part 1: Evaluation and testing within a risk management process". U.S. Food and Drug Administration. 2023. read 9 October 2026. fda.gov
- U.S. Food and Drug Administration. Questions and Answers Regarding Enhancements to the Inactive Ingredient Database (IID). U.S. Food and Drug Administration (CDER). 2019. read 9 October 2026. fda.gov
- International Council for Harmonisation; U.S. Food and Drug Administration (CDER/CBER). Guidance for Industry Q8(R2) Pharmaceutical Development. U.S. Department of Health and Human Services, Food and Drug Administration. 2009;Revision 2. read 9 October 2026. fda.gov
- Carollo M, Cristini I, Crisafulli S, Fontana A, Forti A, Lanaro A, Maccarrone F, Zerio M, Piccoli L, Poluzzi E, Onder G, Trifiro G. Evaluating the impact of medication review and deprescribing on prescribing appropriateness and clinical outcomes in older people residing in long-term care facilities: a systematic review and meta-analysis. 2026. doi:10.1093/ageing/afag084 read 9 October 2026. doi.org/10.1093/ageing/afag084
- Awasthi G, Banerjee S. Merged in silico-in vitro validations of atenolol and amlodipine besylate with excipient interactions for the design of solid oral dosage forms. RSC Pharmaceutics. 2026. doi:10.1039/D6PM00014B read 9 October 2026. doi.org/10.1039/D6PM00014B
- Comoglu T, Ozyilmaz ED. Pharmaceutical excipients in pediatric and geriatric drug formulations: safety, efficacy, and regulatory perspectives. Pharmaceutical Development and Technology. 2025;30(1):1-9. doi:10.1080/10837450.2024.2441181 read 9 October 2026. doi.org/10.1080/10837450.2024.2441181
- Omuya H, Nickel C, Wilson P, Chewning B. A systematic review of randomised-controlled trials on deprescribing outcomes in older adults with polypharmacy. International Journal of Pharmacy Practice. 2023;31(4):349-368. doi:10.1093/ijpp/riad025 read 9 October 2026. doi.org/10.1093/ijpp/riad025
- Jain S, Kaur S, Rathi R, Nagaich U, Singh I. Application of co-processed excipients for developing fast disintegrating tablets: A review. Polymers in Medicine. 2023;53(1):59-68. doi:10.17219/pim/158009 read 9 October 2026. doi.org/10.17219/pim/158009
- Deprescribing Interventions for Older Patients: A Systematic Review and Meta-Analysis. J Am Med Dir Assoc. 2023. doi:10.1016/j.jamda.2023.07.016 read 9 October 2026. doi.org/10.1016/j.jamda.2023.07.016
- Comoglu T, Ozyilmaz ED. Pharmaceutical product development: a "quality by design" (QbD) approach. 2023;1:285-310. doi:10.1016/B978-0-323-91817-6.00001-2 read 9 October 2026. doi.org/10.1016/B978-0-323-91817-6.00001-2
- Liew KB, Hii SH, Helal Uddin ABM, Sarker ZI, Chew YL. Co-processed excipients: a revisit of its development in the past two decades; a review. Journal of Pharmaceutical Negative Results. 2022;13(7):96-103. read 9 October 2026. irep.iium.edu.my
- Rouaz El Hajoui K, Chiclana Rodriguez B, Nardi Ricart A, et al. Excipients in the Paediatric Population: A Review. Pharmaceutics. 2021;13(3):387. doi:10.3390/pharmaceutics13030387 read 9 October 2026. doi.org/10.3390/pharmaceutics13030387
- Jiskoot W, Hawe A, Menzen T, Volkin DB, Crommelin DJA. Ongoing challenges to develop high concentration monoclonal antibody-based formulations for subcutaneous administration: Quo Vadis? Journal of Pharmaceutical Sciences. 2021;111(4):861-867. doi:10.1016/j.xphs.2021.11.008 read 9 October 2026. doi.org/10.1016/j.xphs.2021.11.008
- Wouters OJ, McKee M, Luyten J. Estimated Research and Development Investment Needed to Bring a New Medicine to Market, 2009-2018. JAMA. 2020;323(9):844-853. doi:10.1001/jama.2020.1166 read 9 October 2026. doi.org/10.1001/jama.2020.1166
- Belayneh A, Tadese E, Molla F. Safety and Biopharmaceutical Challenges of Excipients in Off-Label Pediatric Formulations. International Journal of General Medicine. 2020;13:1051-1066. doi:10.2147/IJGM.S280330 read 9 October 2026. doi.org/10.2147/IJGM.S280330
- Liew KB, Gaurav A, Mandal UK. A REVIEW ON CO-PROCESSED EXCIPIENTS: CURRENT AND FUTURE TREND OF EXCIPIENT TECHNOLOGY. International Journal of Pharmacy and Pharmaceutical Sciences. 2019;11(1):1-9. doi:10.22159/ijpps.2019v11i1.29265 read 9 October 2026. doi.org/10.22159/ijpps.2019v11i1.29265
- Milic J, Calija B, Krajisnik D. Excipients functionality: Importance and compendial status. Arhiv za farmaciju. 2016;66(2):71-90. doi:10.5937/arhfarm1602071M read 9 October 2026. doi.org/10.5937/arhfarm1602071M
- Bharate SS, Bharate SB, Bajaj AN. Interactions and incompatibilities of pharmaceutical excipients with active pharmaceutical ingredients: a comprehensive review. Journal of Excipients and Food Chemicals. 2016;1(3). read 9 October 2026. doaj.org
- Apte S. The counter ion: expanding excipient functionality. International Journal of Pharmaceutical Excipients. 2016;2(2). doi:10.66617/001c.1126 read 9 October 2026. doi.org/10.66617/001c.1126
- Carli Lorenzini G, Olsson A. DESIGN TOWARDS BETTER LIFE EXPERIENCE: CLOSING THE GAP BETWEEN PHARMACEUTICAL PACKAGING DESIGN AND ELDERLY PEOPLE. DS 80-9 Proceedings of the 20th International Conference on Engineering Design (ICED 15). 2015;9:065-076. read 9 October 2026. designsociety.org
- Dave VS, Saoji SD, Raut NA, Haware RV. Excipient Variability and Its Impact on Dosage Form Functionality. Journal of Pharmaceutical Sciences. 2015;104(3):906-915. doi:10.1002/jps.24299 read 9 October 2026. doi.org/10.1002/jps.24299
- Narang AS, Desai D, Badawy S. Impact of Excipient Interactions on Solid Dosage Form Stability. Excipient Applications in Formulation Design and Drug Delivery. 2015:93-137. doi:10.1007/978-3-319-20206-8_5 read 9 October 2026. doi.org/10.1007/978-3-319-20206-8_5
- Chin K, Hegarty A, Thielemans L, Schiff R. Thinking outside the box: exploring user and carer perceptions of pharmacy-filled multi-compartment medication compliance aids. doi:10.83033/54ab2e80-a44b-47ec-9043-4b97ca598aba read 9 October 2026. doi.org/10.83033/54ab2e80-a44b-47ec-9043-4b97ca598aba
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 9). The Role of Packaging Design in Drug Development: Regulatory Requirements and Evidence. Pubrica. https://pubrica.com/academy/medical-writing/the-role-of-packaging-design-in-drug-development/
Pubrica Academy. “The Role of Packaging Design in Drug Development: Regulatory Requirements and Evidence.” Pubrica, 9 Oct. 2026, pubrica.com/academy/medical-writing/the-role-of-packaging-design-in-drug-development/.
Pubrica Academy (2026) The Role of Packaging Design in Drug Development: Regulatory Requirements and Evidence. Pubrica. Available at: https://pubrica.com/academy/medical-writing/the-role-of-packaging-design-in-drug-development/ (Accessed: 15 October 2026).
Pubrica Academy. “The Role of Packaging Design in Drug Development: Regulatory Requirements and Evidence.” Pubrica. October 9, 2026. https://pubrica.com/academy/medical-writing/the-role-of-packaging-design-in-drug-development/
Pubrica Academy, ‘The Role of Packaging Design in Drug Development: Regulatory Requirements and Evidence’ (Pubrica, 9 October 2026) <https://pubrica.com/academy/medical-writing/the-role-of-packaging-design-in-drug-development/> accessed 15 October 2026.
Pubrica Academy. The Role of Packaging Design in Drug Development: Regulatory Requirements and Evidence. [Internet]. Pubrica; 2026 Oct 9 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/medical-writing/the-role-of-packaging-design-in-drug-development/
Pubrica Academy, “The Role of Packaging Design in Drug Development: Regulatory Requirements and Evidence,” Pubrica, Oct. 9, 2026. [Online]. Available: https://pubrica.com/academy/medical-writing/the-role-of-packaging-design-in-drug-development/
@misc{the_role_of_packaging_design_in_drug_d_2026,
author = {{Pubrica Academy}},
title = {The Role of Packaging Design in Drug Development: Regulatory Requirements and Evidence},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/medical-writing/the-role-of-packaging-design-in-drug-development/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
Container closure evidence plan
One page per presentation. The four sections are the four areas a reviewer assesses. The degradation pathway should be completed first, because the rest of the protection argument depends on it.
CONTAINER CLOSURE EVIDENCE PLAN
Product: ______________________ Presentation: ______________________
Components (contact materials, closure, liner, secondary): ____________________
Is the presentation named in the quality target product profile? [ ] yes [ ] no
0. CHEMISTRY FIRST
Degradation pathway(s): [ ] hydrolysis [ ] oxidation [ ] photo [ ] other: ______
Therefore the governing barrier property is: ______________________
Preservative present? [ ] no [ ] yes -> sorption assessment required
1. PROTECTION
[ ] Moisture / oxygen transmission data for the SYSTEM (not the resin alone)
[ ] Photostability assessed in the marketed configuration
[ ] Registration stability run in the marketed configuration, desiccant included
Storage condition claimed: ______________________
2. COMPATIBILITY
[ ] Extractables study on each contact material ref: __________
[ ] Leachables study on product in the marketed pack ref: __________
[ ] Sorption of active ingredient assessed ref: __________
[ ] Sorption of preservative assessed (if applicable) ref: __________
3. SAFETY
[ ] Toxicological assessment of identified leachables ref: __________
Threshold applied: __________ Basis for that threshold: __________________
4. PERFORMANCE
Is this a delivery system? [ ] no [ ] yes
If yes:
[ ] Dose accuracy / delivered volume testing ref: __________
[ ] Actuation or injection force ref: __________
[ ] Use-related risk analysis / human factors ref: __________
Sterile product? [ ] no [ ] yes -> [ ] container closure integrity ref: ______
5. REGULATORY BOUNDARIES (name the instrument for each)
Combination product in the US? [ ] no [ ] yes primary mode of action: ________
EU integral drug-device combination (Article 117 opinion)? [ ] no [ ] yes
Child-resistance obligation handled where: ______________________
Guidance version the plan is designed against: ______________________
Regulatory affairs sign-off: __________ date: __________
6. USABILITY CLAIM (only if one is being made)
Claim as it would appear: ______________________
Evidence that would support it: ______________________
Intended users involved in the presentation decision? [ ] no [ ] yes how: ______ Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica writes container closure and pharmaceutical development sections according to the four-area structure that reviewers apply, and assembles the extractables, leachables and toxicological assessment narrative so that each study is demonstrably appropriate for the relevant degradation pathway. Where a usability or adherence claim is made, Pubrica states what the literature supports and designs the review required to support the remainder. Pubrica describes what guidance requires; the sponsor’s regulatory affairs function determines the filing position.